Cunningham AL, et al. - In the ZOE-50 and ZOE-70 trials, the herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster. Researchers here presented the immunogenicity results from those trials. The results demonstrated the development of robust immune responses persisting for 3 years among most HZ/su recipients following vaccination.